Next Article in Journal
Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19
Previous Article in Journal
Banana Lectin from Musa paradisiaca Is Mitogenic for Cow and Pig PBMC via IL-2 Pathway and ELF1
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Age-Associated Characteristics of CD4+ T-Cell Composition in Patients with Atherosclerosis

by
Anastasiia Yu. Filatova
1,*,
Alexandra V. Potekhina
2 and
Tatiana I. Arefieva
1
1
Institute of Experimental Cardiology, National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation, 121552 Moscow, Russia
2
A.L. Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation, 121552 Moscow, Russia
*
Author to whom correspondence should be addressed.
Immuno 2021, 1(3), 277-284; https://doi.org/10.3390/immuno1030019
Submission received: 1 July 2021 / Revised: 8 August 2021 / Accepted: 18 August 2021 / Published: 27 August 2021
(This article belongs to the Section Acquired Immunity)

Abstract

:
Background. We aimed to analyze the contents of the main CD4+ T-cell subsets in patients with atherosclerosis (AS) depending on age. Methods. Male patients with coronary and/or carotid AS, who are non-smokers, and who are receiving statins were divided into three age groups (I—<55 y.o. (n = 23), II—55–64 y.o. (n = 42), III—≥65 y.o. (n = 46)). Leukocyte phenotyping was performed by direct immunofluorescence and flow cytometry. For intracellular cytokine detection, blood mononuclear cells were pre-activated with phorbol 12-myristate 13-acetate and ionomycin in the presence of an intracellular vesicle transport blocker monensin. Results. The groups did not differ in traditional CVD risk factors and AS severity. The content of CD4+ T-cells was lower in group III and II than in group I. The content of CD4+CD25high Treg was lower in group III than in groups I and II. No differences in the quantities of the primed CD39+CD45RA and CD278high Treg, CD4+INFγ+ Th1, CD4+IL17+ Th17, and CD4+IL17+INFγ+ Th1/17 were observed. There were negative correlations between the values of CD4+ T-cells, CD4+CD45RA+ T-cells, CD4+CD25high Treg, CD4+CD25highCD45RA+ Treg, and age. Conclusion. In patients with AS, the age-related depletion of naive CD4+ T-cells also extends to the regulatory compartment. This phenomenon should be considered when studying the impact of the immune cells on the progression of AS.

1. Introduction

CD4+ T-lymphocytes play a major role in the regulation of adaptive immune response [1,2]. Naive CD45RA+ cells leave the thymus to mature in the secondary lymphoid organs into effector and memory cells [3]. Depending on the microenvironment, the activation of naive T-cells leads to their differentiation into effector cells, which are predominantly comprised of T-helpers (Th) type 1 producing INFγ, TNF; Th2 producing IL-4, -5, -10, -13, etc.; and Th17 producing IL-17 and -22 [2]. The main contribution of regulatory T-cells (Tregs) to immune homeostasis is to prevent or limit effector T-cell activation. Tregs are characterized by the intracellular expression of transcription factor Foxp3, high membrane exposure of CD25, and the ability to produce anti-inflammatory cytokines TGFβ and IL-10. Naturally occurring Tregs develop primarily in the thymus, while inducible Tregs can also differentiate in the periphery during an active immune response [4].
Atherosclerosis (AS) is a chronic inflammatory disorder resulting from the accumulation of oxidized lipoproteins and other pro-atherogenic substances in the arterial intima [5]. It is hypothesized that a wide range of T-lymphocyte subtypes with different functions are involved in atherogenesis. Th1 contribute to maintenance of the inflammatory process and the acceleration of atherosclerosis [6,7]. Tregs were shown to possess anti-inflammatory and anti-atherogenic effects [8,9,10,11]. Data on the role of Th17 in the development of atherosclerosis are contradictory [12,13,14,15]; however, the majority of studies showed a pro-inflammatory activity of this cell type [16,17,18,19,20]. Th1/17 is a small subset of Th17 capable of producing both IL-17 and INFγ. Increased blood frequencies of Th1/17 are associated with several autoimmune/inflammatory diseases, including atherosclerosis [14,21,22].
Age-related changes in the immune system are an important factor promoting the emergence and maintenance of chronic inflammatory diseases. Despite the data showing a decrease in the number of T-lymphocytes with age due to thymic involution, the composition of minor T-cell subpopulations including Tregs needs to be better understood. Several studies demonstrated an increase in Treg blood content and suppressive capacity in older people [23,24,25], while others did not observe any age-related changes in the Treg population [26]. Data on the state of effector subpopulations are sparse, with one recent paper showing some increases in the Th1 and Th17 blood contents in older healthy donors [27].
In the present study, we compared the blood content of CD4+ lymphocyte subpopulations, including the main effector and regulatory subsets, in patients with atherosclerosis of coronary and carotid arteries in different age groups.

2. Materials and Methods

The study was approved by the Institutional Ethics Committee. Written consent was obtained from each patient. A total of 120 non-smoking male patients with stable coronary artery disease who were scheduled for a coronary angiography were enrolled. Nine patients were excluded because coronary angiography was not performed. The severities of coronary and carotid AS were assessed using a coronary angiography and a vascular ultrasound, respectively. The exclusion criteria included acute coronary syndrome or interventions in the previous 6 months, history of stroke, neoplasms, liver or renal failure, infectious/inflammatory disease, decompensated diabetes mellitus, current use of immunosuppressive drugs, and smoking over the past 3 years. All patients had been receiving standard therapy with beta-blockers, acetylsalicylic acid/clopidogrel, ACE inhibitors/sartans, and statins.
Coronary angiography was performed via a trans-radial approach using a standard technique. The severity of coronary AS was determined by the degree of stenosis of the main coronary artery and assessed by one experienced independent observer. Coronary AS was defined as mild if no lesions beyond mild luminal irregularities were observed and if the stenosis was <40% of the lumen narrowing; median if the stenosis was >50%, or previous stenting of one or two coronary arteries; and severe if the stenosis was >50%, or previous stenting of 3 or more coronary arteries.
Duplex scanning of the carotid arteries was performed using a high-resolution ultrasound system with a linear array transducer 3–9 MHz. Atherosclerotic plaques were assessed in the distal parts of the common carotid artery (CCA), in the CCA bifurcation, and in the internal carotid artery (ICA) bilaterally in the longitudinal (anterior, lateral, and posterior planes) and transversal views. The severity of the carotid artery stenosis was determined using the ECST criteria (baseline stenosis site artery diameter/stenosis site artery diameter × 100%) [28].

2.1. Lymphocyte Immunophenotyping

Whole blood was collected in a sodium citrate anticoagulated vacutainer tube. The samples were processed within 2 h after being collected. For surface antigen staining, the following antibodies and reagents were used: CD3-FITC, CD3-PerCP, CD4-FITC, CD25-PE, CD127-PC5, CD39-FITC, CD45-APC, CD45RA-APC, CD278-APC, and lysing and fixing solutions (Beckman Coulter, Becton Dickinson Immunocytometry Systems, eBioscience, San Diego, CA, USA). The intracellular antigens analysis was performed in mononuclear leukocytes. The cells were isolated using density gradient centrifugation (Histopaque-1077, Sigma-Aldrich, St. Louis, MO, USA). For cytokine detection, mononuclear cells were additionally cultivated in the presence of 25 ng/mL PMA, 1 μg/mL ionomycin, and 10 μg/mL monensin for 4 h. Cell staining was performed with CD4-PC5, FoxP3-Alexa488, INFγ-PE, IL17a-Alexa488, and relevant isotypic controls and with a FoxP3 Staining Buffer Set (all reagents from eBioscience, San Diego, CA, USA) per the manufacturer’s manual. The samples were analyzed with a two-laser FACS Caliber flow cytometer equipped with CellQuest Pro software (Becton Dickinson Immunocytometry Systems). Lymphocytes were identified by light scattering parameters and CD45 expression pattern. Tregs were identified as CD4+CD25high (including CD45RA+ naïve and CD45 memory subsets) and CD4+Foxp3+, Th1 was identified as CD4+INFγ+, Th17 was identified as CD4+IL17a+ cells, and Th1/17 was identified as CD4+IL17a+INFγ+ (Figure 1).

2.2. Statistics

The data are presented as a median (25–75th percentile). Kruskal–Wallis ANOVA and Mann–Whitney U tests were used in multiple or paired comparisons, respectively. Chi-square or Fisher’s exact two-tailed test was used in multiple or paired comparisons of binary features, respectively. Spearman’s test was used for correlation analysis. The differences were considered statistically significant at p < 0.05.

3. Results

A total of 111 patients (median age 63 (55; 69)) were categorized into three groups according to age (I—<55 y.o. (n = 23), II—55–64 y.o. (n = 42), III—≥65 y.o. (n = 46)). The groups were comparable in the traditional cardiovascular disease risk factors, coronary and carotid AS severity (Table 1), and medical treatment.
In patients over 65 years of age (group III), the absolute values of CD4+ T-cells and CD4+CD45RA+ T-cells, CD4+CD25high, and CD4+CD25highCD45RA+ Tregs were lower compared with those in groups I and II. The number of CD4+CD25highCD39+CD45RA and CD4+CD25high278high Tregs did not change (Table 1). The absolute content of CD4+Foxp3+ Treg was lower in groups II and III vs. group I, but the differences did not achieve statistical significance.
The number of circulating Th17 and Th1 did not change depending on age (Table 2).
Negative correlations were observed between absolute values of CD4+ T-cells (r = −0.28), CD4+CD25high Treg (r = −0.27), CD4+CD25highCD45RA+ Treg (r = −0.24), CD4+CD45RA+ T-cells (r = −0.36), CD4+CD45RA+/CD4+CD45RA T-cells ratio (r = −0.24), and age (p < 0.05).

4. Discussion

Age-related changes affect both innate and adaptive immunity. During aging, the number and repertoire of T-cells markedly are reduced due to thymus involution accompanied with the accumulation of memory cells and imbalance between CD4+ and CD8+ T-cells, with an increasing prevalence of CD8+ [29,30,31,32,33]. The age-related enhancement of myelopoiesis is also associated with the suppression of proliferation and functional activity of T-cells [34]. The pool of naive T-cells and memory T-cells of the elderly is characterized by telomere shortening and replicative senescence [35]. Further accumulation of DNA damage in T-cells, activation of the catalytic subunit of DNA-dependent protein kinase, and the NF-kB transcription factor guide the polarization of T-cells to a pro-inflammatory phenotype with high expressions of INFγ, TNF, and IL-1 and -6 [31], and systemic inflammatory conditions are associated with advanced age [36].
The data on age-related changes in Tregs are contradictory. The relative values, phenotypic characteristics, and inhibitory ability of CD4+Foxp3+ Treg were comparable in young (<40 years old) and older (>65) healthy people [26]. Conversely, decreased production of anti-inflammatory cytokine IL-10 was observed during co-cultivation of CD4+Foxp3+ Treg and CD4+CD25 T-cells obtained from the older subjects, which was not mediated by changes in CTLA-4 expression or apoptosis.
Several studies have shown an increase in the frequencies of circulating Tregs during aging. Gregg et al. [23] observed an age-associated increase in the relative and absolute values of CD4+CD25high Treg in healthy volunteers, and no differences were found in the expression of surface markers of T-cell activation (CD69, HLA-DR, CD71, and CTLA-4) or in the suppressive capacity of Treg; however, the number of CD45RO+ cells was higher in older people. The frequencies of CD4+Foxp3+ Treg in the blood of older subjects without confirmed disease was significantly higher than that in their younger counterparts; the former demonstrated a preserved or slightly increased expression of CTLA-4 and GITR, associated with the suppressive function of Treg, and a comparable expression of chemokine receptors CCR5 and CCR7 that mediate migration and homing [25].
The contradictory data on the composition of T-cell subsets in different age groups may be associated with heterogeneity of patients by gender and concomitant diseases. The frequencies of circulating CD4+ T-cells are higher in women [37], and there are gender-associated differences in cytokine production (INFγ and IL-17) [38] and in autoimmune disease predominance and progression [39].
We studied age-related changes in the composition of CD4+ lymphocytes in a homogeneous group of non-smoking male patients with confirmed atherosclerotic disease of the coronary and carotid arteries. The frequencies of circulating CD4+ T-cells and CD4+CD25high Treg decreased with age in patients with atherosclerosis. The insufficient decrease in CD4+Foxp3+ Treg in contrast with the decline in CD4+CD25high Treg was probably due to the partial compensation via induction of Treg in the periphery. These age-related alterations could be explained with a decrease in thymic production of naive lymphocytes, which leads to insufficient replenishment of T-cells with naive CD45RA+ lymphocytes. This is evidenced by the negative correlations between age and the content of CD45RA+ populations, including Tregs. Our data are consistent with the previously published comparison of the phenotype and functional characteristics of Treg in older and young, apparently healthy donors, with the former demonstrating a decrease in the level of naive CD45RA+ Treg and an increase in the level of cytokine-producing CD45RA Treg [40]. The relative content of Treg and CD45RA+CD45RO naïve Treg is lower in patients with acute coronary syndrome compared with patients with stable angina or non-coronary chest pain syndrome; the content of CD45RACD45RO+ Treg was comparable between groups [41]. We assume that Treg deficiency, which develops due to a decrease in the number of naive cells, may have a pathogenetic relationship with the initiation and destabilization of atherosclerosis. Further research is required to confirm this hypothesis.

5. Conclusions

In patients with AS, the age-related depletion of naive CD4+ T-cells also extends to the regulatory compartment. This phenomenon should be considered when studying the impact of the immune cells on the progression of AS.

Author Contributions

Conceptualization A.Y.F., A.V.P. and T.I.A.; methodology A.Y.F. and T.I.A.; validation A.Y.F., A.V.P. and T.I.A.; investigation A.Y.F. and T.I.A.; resources T.I.A. and A.V.P.; writing—original draft preparation, A.Y.F.; writing—review and editing, T.I.A. and A.V.P.; supervision T.I.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding. The study was approved by the Russian Ministry of Health, project No. АААА-А19-119022290045-1.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of National Medical Research Center of Cardiology of Ministry of Healthcare of Russian Federation (protocol No. 249 from 30 September 2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zhou, X.; Robertson, A.-K.L.; Rudling, M.; Hansson, G.K. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ. Res. 2005, 96, 427–434. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Saigusa, R.; Winkels, H.; Ley, K. T cell subsets and functions in atherosclerosis. Nat. Rev. Cardiol. 2020, 17, 387–401. [Google Scholar] [CrossRef] [PubMed]
  3. Ventevogel, M.; Sempowski, G.D. Thymic rejuvenation and aging. Curr. Opin. Immunol. 2013, 25, 516–522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Kaun, R.; Agrawal, D.K.; Thankam, F.G. Treg cells in atherosclerosis. Mol. Biol. Rep. 2021, 48, 4897–4910. [Google Scholar] [CrossRef] [PubMed]
  5. Wolf, D.; Ley, K. Immunity and inflammation in atherosclerosis. Circ. Res. 2019, 124, 315–327. [Google Scholar] [CrossRef]
  6. Zhao, Z.; Wu, Y.; Cheng, M.; Ji, Y.; Yang, X.; Liu, Y.; Jia, S.; Yuan, Z. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis 2011, 217, 518–524. [Google Scholar] [CrossRef] [PubMed]
  7. Fernandez, D.M.; Rahman, A.H.; Fernandez, N.F.; Chudnovskiy, A.; Amir, E.D.; Amadori, L.; Khan, N.S.; Wong, C.K.; Shamailova, R.; Hill, C.A.; et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 2019, 25, 1576–1588. [Google Scholar] [CrossRef]
  8. Mor, A.; Luboshits, G.; Planer, D.; Keren, G.; George, J. Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes. Eur. Heart J. 2006, 27, 2530–2537. [Google Scholar] [CrossRef] [Green Version]
  9. George, J.; Schwartzenberg, S.; Medvedovsky, D.; Jonas, M.; Charach, G.; Afek, A.; Shamiss, A. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis 2012, 222, 519–523. [Google Scholar] [CrossRef]
  10. Wigren, M.; Bjorkbacka, H.; Andersson, L.; Ljungcrantz, I.; Fredikson, G.N.; Persson, M.; Bryngelsson, C.; Hedblad, B.; Nilsson, J. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2000–2004. [Google Scholar] [CrossRef] [Green Version]
  11. Potekhina, A.V.; Pylaeva, E.; Provatorov, S.; Ruleva, N.; Masenko, V.; Noeva, E.; Krasnikova, T.; Arefieva, T. Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis. Atherosclerosis 2015, 238, 17–21. [Google Scholar] [CrossRef] [PubMed]
  12. Hashmi, S.; Zeng, Q.T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron. Artery Dis. 2006, 17, 699–706. [Google Scholar] [CrossRef] [PubMed]
  13. Cheng, X.; Yu, X.; Ding, Y.-J.; Fu, Q.-Q.; Xie, J.-J.; Tang, T.-T.; Yao, R.; Chen, Y.; Liao, Y.-H. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol. 2008, 127, 89–97. [Google Scholar] [CrossRef]
  14. Eid, R.E.; Rao, D.A.; Zhou, J.; Lo, S.L.; Ranjbaran, H.; Gallo, A.; Sokol, S.I.; Pfau, S.; Pober, J.S.; Tellides, G. Interleukin-17 and interferon-γ are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119, 1424–1432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Simon, T.; Taleb, S.; Danchin, N.; Laurans, L.; Rousseau, B.; Cattan, S.; Motely, J.-M.; Dubourg, O.; Tedgui, A.; Kotti, S.; et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur. Heart J. 2013, 34, 570–577. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. De Boer, O.; der Meer, J.J.; Teeling, P.; van der Loos, C.M.; Idu, M.M.; van Maldegem, F.; Aten, J.; van der Wal, A.C. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J. Pathol. 2010, 220, 499–508. [Google Scholar] [CrossRef] [PubMed]
  17. Erbel, C.; Dengler, T.J.; Wangler, S.; Lasitschka, F.; Bea, F.; Wambsganss, N.; Hakimi, M.; Bockler, D.; Katus, H.A.; Gleissner, C.A. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res. Cardiol. 2011, 106, 125–134. [Google Scholar] [CrossRef]
  18. Wang, Z.; Lee, J.; Wang, H.; Liu, X.; Shang, F.; Zheng, Q. Increased Th17 cells in coronary artery disease are associated with neutrophilic inflammation. Scand. Cardiovasc. J. 2011, 45, 54–61. [Google Scholar] [CrossRef] [PubMed]
  19. Filatova, A.Y.; Pylaeva, E.A.; Potekhina, A.V.; Osokina, A.K.; Pogorelova, O.A.; Tripoten, M.I.; Balakhonova, T.V.; Provatorov, S.I.; Noeva, E.A.; Klesareva, E.A.; et al. Subpopulation composition of CD4+ T-lymphocytes as factor contributing to the progression of atherosclerosis of carotid arteries. Kardiologiia 2017, 57, 64–71. [Google Scholar] [CrossRef]
  20. Filatova, A.Y.; Potekhina, A.V.; Pylaeva, E.A.; Osokina, A.K.; Ruleva, N.Y.; Pogorelova, O.A.; Tripoten, M.I.; Noeva, E.A.; Balakhonova, T.V.; Masenko, V.P.; et al. The severity of internal carotid artery stenosis is associated with the circulatinf Th17 level. Heliyon 2020, 6, e03856. [Google Scholar] [CrossRef]
  21. Tsanaktsi, A.; Solomou, E.E.; Liossis, S.-N. Th1/17 cells, a subset of Th17, are expanded in patients with active systemic lupus erythematosus. Clin. Immunol. 2018, 195, 101–106. [Google Scholar] [CrossRef] [PubMed]
  22. Ma, Q.; Ran, H.; Li, Y.; Lu, Y.; Liu, X.; Huang, H.; Yang, W.; Yu, L.; Chen, P.; Huang, X.; et al. Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. Clin. Immunol. 2020, 218, 108492. [Google Scholar] [CrossRef] [PubMed]
  23. Gregg, R.; Smith, C.M.; Clark, F.J.; Dunnion, D.; Khan, N.; Chakraverty, R.; Nayak, L.; Moss, P.A. The number of human peripheral blood CD4+CD25high regulatory T cells increases with age. Clin. Exp. Immunol. 2005, 140, 540–546. [Google Scholar] [CrossRef] [PubMed]
  24. Gottenberg, J.-E.; Lavie, F.; Abbed, K.; Gasnault, J.; Nevot, E.L.; Delfraissy, J.-F.; Taoufik, Y.; Mariette, X. CD4+CD25high regulatory T cells are not impaired in patients with primary Sjögren’s syndrome. J. Autoimmun. 2005, 24, 235–242. [Google Scholar] [CrossRef]
  25. Lages, C.S.; ISuffia, I.; Velilla, P.A.; Huang, B.; Warshaw, G.; Hildeman, D.A.; Belkaid, Y.; Chougnet, C. Functional Regulatory T Cells Accumulate in Aged Hosts and Promote Chronic Infectious Disease Reactivation. J. Immunol. 2008, 181, 1835–1848. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Hwang, K.-A.; Kim, H.-R.; Kang, I. Aging and human CD4+ regulatory T cells. Mech. Ageing Dev. 2009, 130, 509–517. [Google Scholar] [CrossRef] [Green Version]
  27. Botafogo, V.; Perez-Andres, M.; Jara-Acevedo, M.; Barcena, P.; Grigore, G.; Hernandez-Delgrado, A.; Damasceno, D.; Comans, S.; Blanco, E.; Romero, A.; et al. Age distribution of multiple functionally relevant subsets of CD4+ T cells in human blood using a standardized and validated 14-color euroflow immune monitoring tube. Front. Immunol. 2020, 11, 166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. European Carotid Surgery Trialists’ Collaborative Group. MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet 1991, 337, 1235–1243. [Google Scholar] [CrossRef]
  29. Ferguson, F.G.; Wikby, A.; Maxson, P.; Olsson, J.; Johansson, B. Immune parameters in a longitudinal study of a very old population of Swedish people: A comparison of survivors and nonsurvivors. J. Gerontol. Biol. Sci. 1995, 50, 378–382. [Google Scholar] [CrossRef]
  30. Wikby, A.; Maxson, P.; Olsson, J.; Johansson, B.; Ferguson, F.G. Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: The Swedich longitudinal OCTO-immune study. Mech. Ageing Dev. 1998, 102, 187–198. [Google Scholar] [CrossRef]
  31. Zanni, F.; Vescovini, R.; Biasini, C.; Fagnoni, F.; Zanlari, L.; Telera, A.; Di Pede, P.; Passeri, G.; Pedrazzoni, M.; Passeri, M.; et al. Marked increase with age of type 1 cytokines within memory and effector/cytotoxic CD8+ T cells in humans: A contribution to understand the relationship between inflammation and immunosenescence. Exp. Gerontol. 2003, 38, 981–987. [Google Scholar] [CrossRef]
  32. Huppert, F.A.; Pinto, E.M.; Morgan, K.; Brayene, C. Survival in a population sample is predicted by proportions of lymphocyte subsets. Mech. Ageing Dev. 2003, 124, 449–451. [Google Scholar] [CrossRef]
  33. Thapa, P.; Farber, D.L. The role of the thymus in the immune response. Thorac. Surg. Clin. 2019, 29, 123–131. [Google Scholar] [CrossRef] [PubMed]
  34. Alves, A.S.; Bueno, V. Immunosenescence: Participation of T lymphocytes and myeloid-derives supressor cells in aging-related immune response changes. Einstein 2019, 17, eRB4733. [Google Scholar] [CrossRef] [Green Version]
  35. Tortorella, C.; Loria, M.P.; Piazzolla, G.; Schulze-Koops, H.; Lipsky, P.E.; Jirillo, E.; Antonaci, S. Age-related impairment of T cell proliferative responses related to the decline of CD28+ T cell subsets. Arch. Gerontol. Geriatr. 1998, 26, 55–70. [Google Scholar] [CrossRef]
  36. Olivieri, F.; Albertini, M.C.; Orciani, M.; Ceka, A.; Cricca, M.; Procopio, A.D.; Bonafe, M. DNA damage response (DDR) and senescence: Shuttled inflamma-miRNAs on the stage of inflamm-aging. Oncotarget 2015, 6, 35509–35521. [Google Scholar] [CrossRef] [Green Version]
  37. Amadori, A.; Zamarchi, R.; De Silvestro, G.; Forza, G.; Cavatton, G.; Danieli, G.A.; Clementi, M.; Chieco-Bianchi, L. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat. Med. 1995, 1, 1279–1283. [Google Scholar] [CrossRef] [PubMed]
  38. Zhang, M.A.; Rego, D.; Moshkova, M.; Kebir, H.; Chruscinski, A.; Nguyen, H.; Akkermann, R.; Stanczyk, F.Z.; Prat, A.; Steinman, L.; et al. Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way. Proc. Natl. Acad. Sci. USA 2012, 109, 9505–9510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Fairweather, D.; Frisancho-Kiss, S.; Rose, N.R. Sex differences in autoimmune disease from a pathological perspective. Am. J. Pathol. 2008, 173, 600–609. [Google Scholar] [CrossRef] [Green Version]
  40. Miyara, M.; Yoshioka, Y.; Kitoh, A.; Shima, T.; Wing, K.; Niwa, A.; Parizot, C.; Taflin, C.; Heike, T.; Valeyre, D.; et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the Foxp3 transcription factor. Immunity 2009, 30, 899–911. [Google Scholar] [CrossRef] [Green Version]
  41. Zhang, W.; Wang, J.; Shu, Y.; Tang, T.; Zhu, Z.; Xia, N.; Nie, S.; Liu, J.; Zhou, S.; Li, J.; et al. Impaired thymic export and increased apoptosis account for regulatory T cell defects in patients with non-ST segment elevation acute coronary syndrome. J. Biol. Chem. 2012, 287, 34157–34166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Figure 1. Flow cytometric analysis (gating strategies) of CD4+ T-cells subpopulations.
Figure 1. Flow cytometric analysis (gating strategies) of CD4+ T-cells subpopulations.
Immuno 01 00019 g001aImmuno 01 00019 g001b
Table 1. Clinical characteristics of patients with atherosclerosis in different age groups.
Table 1. Clinical characteristics of patients with atherosclerosis in different age groups.
ParameterI (<55, n = 23)II (55–64, n = 42)III (≥65, n = 46)p
BMI, kg/m229.0 (28.0; 33.0)28.0 (25.0; 30.0)27.0 (26.0; 29.0)0.07
Arterial hypertension, n (%) 20 (87%)35 (83%)41 (89%)0.87
Diabetes mellitus, n (%) 2 (8%)1 (2%)6 (13%)0.18
Previous myocardial infarction, n (%)12 (52%)25 (59%)24 (52%)0.75
Coronary AS severity
mild, n (%)
moderate, n (%)
severe, n (%)
1 (4)
12 (52)
10 (43)
4 (9)
26 (62)
12 (28)
1 (2)
23 (50)
22 (48)
0.28
CCA/CCA bifurcation stenosis, %37.5 (30.0; 45.0)30.0 (30.0; 40.0)40.0 (30.0; 45.0)0.21
ICA stenosis, %40.0 (35.0; 50.0)37.5 (30.0; 50.0)40.0 (25.0; 60.0)0.62
Severe coronary AS + carotid artery stenosis > 50%, n (%)2 (8%)0 (0%)4 (8%)0.41
Total cholesterol, mM 3.8 (3.6; 4.5)4.2 (3.5; 4.8)4.0 (3.6; 4.7)0.67
Triglycerides, mM 1.4 (1.1; 2.2)1.4 (1.2; 1.8)1.5 (1.0; 1.8)0.94
LDL, mM 2.2 (1.8; 2.5)2.2 (1.7; 2.9)2.2 (1.7; 2.9)0.78
HDL, mM 0.9 (0.8; 1.1)1.1 (0.9; 1.2)1.0 (0.8; 1.2)0.77
Glucose, mM 5.7 (5.2; 6.1)5.4 (5.1; 6.1)5.6 (5.0; 6.2)0.69
Leukocytes, mln/mL 7.2 (6.2; 8.4)7.4 (5.8; 8.4)7.0 (6.0; 8.0)0.73
The data are presented as a median (25%; 75%) or n (%).
Table 2. Immunological parameters of patients with atherosclerosis in different age groups.
Table 2. Immunological parameters of patients with atherosclerosis in different age groups.
ParameterI (<55, n = 23)II (55–64, n = 42)III (≥65, n = 46)p
Lymphocytes, mln/mL2.1 (1.6; 2.6)1.9 (1.5; 2.2)1.8 (1.4; 2.2)0.22
CD4+ T-cells (103/mL)903.0 (585.6; 1113.8)745.4 (502.2; 924.0)646.3 (516.0; 806.4)0.03
1 vs. 3 p = 0.008
2 vs. 3 p = 0.06
CD4+CD45RA+ T-cells (103/mL)365.0 (262.3; 478.2)422.3 (241.1; 553.0)197.2 (173.5; 297.5)1 vs. 3 p = 0.0008
2 vs. 3 p = 0.0007
CD4+CD45RA+/CD4+CD45RA T-cells0.23 (0.15; 0.33)0.23 (0.10; 0.30)0.16 (0.09; 0.24)1 vs. 3 p = 0.016
2 vs. 3 p = 0.057
CD4+CD25highCD127low Treg (103/mL)35.0 (28.7; 54.4)31.0 (21.1; 43.6)24.2 (18.4; 35.2)1 vs. 3 p = 0.008
2 vs. 3 p = 0.03
CD4+CD25highCD39+CD45RA Treg (% CD25high Treg)53.5 (31.4; 64.3)56.0 (21.5; 64.5)57.4 (45.1; 68.0)0.69
CD4+CD25highCD278high Treg (% CD25high Treg)86.5 (82.0; 88.5)86.5 (82.0; 90.0)90.0 (88.0; 93.0)0.11
CD4+CD25highCD45RA+Treg (103/mL)8.5 (6.1; 14.3)6.6 (3.5; 12.7)5.7 (2.2; 9.7)1 vs. 3 p = 0.01
CD4+Foxp3+ Treg (103/mL)74.0 (53.5; 87.2)58.0 (35.0; 73.6)54.0 (38.4; 73.3)0.19
Th17 (103/mL)13.4 (8.1; 14.7)9.6 (4.8; 15.8)11.3 (5.8; 16.6)0.66
Th1 (103/mL)212.0 (158.0; 258.7)142.3 (55.6; 225.0)143.5 (98.4; 239.7)0.19
Th1/17 (103/mL)2.0 (1.4; 4.2)2.0 (1.1; 3.7)1.4 (0.6; 3.1)0.52
The data are presented as a median (25%; 75%) or n (%).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Filatova, A.Y.; Potekhina, A.V.; Arefieva, T.I. Age-Associated Characteristics of CD4+ T-Cell Composition in Patients with Atherosclerosis. Immuno 2021, 1, 277-284. https://doi.org/10.3390/immuno1030019

AMA Style

Filatova AY, Potekhina AV, Arefieva TI. Age-Associated Characteristics of CD4+ T-Cell Composition in Patients with Atherosclerosis. Immuno. 2021; 1(3):277-284. https://doi.org/10.3390/immuno1030019

Chicago/Turabian Style

Filatova, Anastasiia Yu., Alexandra V. Potekhina, and Tatiana I. Arefieva. 2021. "Age-Associated Characteristics of CD4+ T-Cell Composition in Patients with Atherosclerosis" Immuno 1, no. 3: 277-284. https://doi.org/10.3390/immuno1030019

APA Style

Filatova, A. Y., Potekhina, A. V., & Arefieva, T. I. (2021). Age-Associated Characteristics of CD4+ T-Cell Composition in Patients with Atherosclerosis. Immuno, 1(3), 277-284. https://doi.org/10.3390/immuno1030019

Article Metrics

Back to TopTop